EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hesperidin Ameliorates Sarcopenia through the Regulation of Inflammaging and the AKT/mTOR/FoxO3a Signaling Pathway in 22–26-Month-Old Mice

Hyun-Ji Oh, Heegu Jin, Boo-Yong Lee

Cells · 2023

DOI: 10.3390/cells12152015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Hyun-Ji Oh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Food Science and Biotechnology, College of Life Science, CHA University, Seongnam 13488, Gyeonggi, Republic of Korea. Hauptthemen laut MEDLINE: Sarcopenia, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases, Signal Transduction. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Yangyoung Foundation in Korea, National Research Foundation of Korea (NRF) funded by the Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Faced with a globally aging society, the maintenance of health and quality of life in older people is very important. The age-related loss of muscle mass and strength, known as sarcopenia, severely reduces quality of life and increases the risks of various diseases. In this study, we investigated the inhibitory effect of hesperidin (HES) on inflammaging, with the intention of evaluating its potential use as a treatment for sarcopenia. We studied 22–26-month-old mice, corresponding to humans aged ≥70 years, with aging-related sarcopenia, and young mice aged 3–6 months. The daily administration of HES for 8 weeks resulted in greater muscle mass and strength and increased the fiber size of the old mice. HES also restored the immune homeostasis that had been disrupted by aging, such as the imbalance in M1/M2 macrophage ratio. In addition, we found that HES ameliorated the sarcopenia by regulating AKT/mammalian target of rapamycin/forkhead box 3a signaling through an increase in insulin-like growth factor (IGF)-1 expression in the old mice. Therefore, HES represents a promising candidate inhibitor of sarcopenia in older people, and its effects are achieved through the maintenance of immune homeostasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcopeniaProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesSignal TransductionForkhead Box Protein O3HesperidinAgingInflammationAnimalsMiceMaleMice, Inbred C57BLInsulin-Like Growth Factor IMuscle, SkeletalHumans

Stichwörter der Autor:innen

AKT/mammalian target of rapamycin/forkhead box 3a signaling pathwayaginghesperidininflammaginginsulin growth factor-1sarcopenia

Substanzen

Proto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesForkhead Box Protein O3HesperidinFoxO3 protein, mouseInsulin-Like Growth Factor ImTOR protein, mouse

Autor:innen und Institutionen

  • Department of Food Science and Biotechnology, College of Life Science, CHA University, Seongnam 13488, Gyeonggi, Republic of Korea.

Förderung

  • National Research Foundation of Korea
  • Yangyoung Foundation in Korea
  • National Research Foundation of Korea (NRF) funded by the Ministry of Education

Zitieren

APA

Oh, H. J., Jin, H., & Lee, B. Y. (2023). Hesperidin Ameliorates Sarcopenia through the Regulation of Inflammaging and the AKT/mTOR/FoxO3a Signaling Pathway in 22–26-Month-Old Mice. Cells. https://doi.org/10.3390/cells12152015

Vancouver

Oh HJ, Jin H, Lee BY. Hesperidin Ameliorates Sarcopenia through the Regulation of Inflammaging and the AKT/mTOR/FoxO3a Signaling Pathway in 22–26-Month-Old Mice. Cells. 2023. doi:10.3390/cells12152015

BibTeX
@article{Oh2023,
  author = {Oh, Hyun-Ji and Jin, Heegu and Lee, Boo-Yong},
  title = {Hesperidin Ameliorates Sarcopenia through the Regulation of Inflammaging and the AKT/mTOR/FoxO3a Signaling Pathway in 22–26-Month-Old Mice},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12152015}
}
Kostenlos starten →